MY2022 EVO 1.0

When your ultrasound device workflow is driven by Artificial Intelligence (A.I.), extended connectivity and the multimodality approach, your horizons in radiology imaging are broadened.
The newly released MY2022 EVO 1.0 lets you take one step forward in simplifying your workflow and gives you new features.

Liver Package extension

MY2022 EVO 1.0 offers a complete solution for a multiparametric approach to the liver. Esaote's new **QAI** (Quantification Attenuation Imaging) technology provides a reliable quantification of liver attenuation completing the stiffness assessment provided by **QElaXto 2D** to give you an overview of the liver condition and support diagnosis and follow-up. To leverage the detection and characterization of suspect lesions, Esaote's Liver Package offers an evolution of **microV** technology, to take advantage of its sensitivity and the higher frame rate of color Doppler imaging. MY2022 EVO 1.0 also boosts **CnTI™**, Esaote's Contrast Enhanced Ultrasound technology, increases performance via considerable persistency of the contrast media and improves coverage of the deepest areas.



UroFusion technology powered by A.I. for targeted prostate biopsies

UroFusion helps you reach a new level in the simplicity of fusion imaging for targeted prostate biopsies. Supported by A.I.-driven workflow solution, this advanced Esaote technology is now reaching a level of workflow simplification never obtained before in MRI dataset registration with real-time ultrasound, in both transperineal and transrectal approaches.



NEVER STOP SEEING THE UNSEEN.

esaote

BreastNav™ & BreastNav™ MRI technologies

BreastNav™ & **BreastNav™ MRI** covers the full breast package for a multiparametric and multimodality approach in one of the most mobile and variable organs in the human body, giving real-time feedback on the scanned area, for easy follow-up on a specific target. In particular, BreastNav™ MRI – based on 3D-modeled A.I. technology – offers fusion imaging between prone MRI and supine US.





MY2022 EVO 1.0 for MyLab™X9, MyLab™9 Platform and MyLab™X8 Platform

Powered by A.I., @Detect technology for automatic contouring of lesions in superficial imaging

@Detect is a brand-new technology supported by A.I. to increase the speed and consistency of lesions segmentation and helps in providing reliable measurements of the suspected area.





Shared service package extension

MY2022 EVO 1.0 covers a 360° shared-service solution, embedding new workflow solutions powered by **A.I.** in cardiovascular and women's health applications. In cardiology, **AutoEF** offers an automatic contouring ejection fraction quantification in 4 and 2 chambers; **XStrain™** enables zero-click detection of the endocardial border profiles in the left ventricle and provides strain assessment of the right ventricle. In obstetrics examinations, MY2022 EVO 1.0 embeds 3D flow representation, via **BrightFlow** technology. It also extends the Esaote **AutoOB** package to 11 measurements and integrates an A.I.-powered automatic plane recognition algorithm to facilitate the workflow and increase your confidence.







0123

Esaote S.p.A – sole-shareholder company
Via Enrico Melen 77, 16152 Genova, ITALY, Tel. +39 010 6547 1, Fax +39 010 6547 275, info@esaote.com

Visit us online
for more information.

1600004111MA Ver.01